This finding supports our hypothesis that combinations
of plant extracts and chemotherapeutic agents allow a reduction
in the dosage of the latter (i.e., doxorubicin and
cisplatin), yet retaining the benefits but minimizing the cytotoxic
effects, thus enhancing therapeutic efficacy